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Introduction
Nasopharyngeal carcinoma (NPC) is one of the most
common head and neck cancers in Southeast Asia,
including Taiwan, and has special geographic and eth-
nic distributions, with particularly high rates among
southeastern Chinese and other individuals of Chinese
descent. In addition to the Epstein–Barr virus (EBV),
epidemiologic studies have suggested that environ-
mental and host factors play important roles in the
development of NPC. Cigarette smoking and Can-
tonese salted fish were shown to be associated with
this disease,1,2 and in addition to environmental fac-
tors, familial clustering of NPC has long been docu-
mented in Chinese and other populations. The
contribution of genetic factors to the carcinogenesis 
of NPC was supported by the finding that first-
degree relatives of NPC patients had a greater risk of
NPC.2 Furthermore, specific genotypes among certain
genetic polymorphisms were found to be associated
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with susceptibility to NPC.3–7 Genetic polymorphisms
associated with susceptibility to NPC are being studied
with great interest, especially single nucleotide poly-
morphisms (SNPs). 
Recent studies have shown that human leukocyte
antigen (HLA)-A and B alleles are associated with sus-
ceptibility to NPC, and suggested that other candi-
date genes might lie within or near HLA.6,7 Notably,
the tumor necrosis factor- (TNF-) gene occurs near
the genomic segment between HLA-class I and II
genes. TNF- is a pro-inflammatory cytokine and may
play a role in inflammatory pathways that increase
tumorigenesis.8 TNF- has been found in high con-
centrations in patients with cancer,9,10 and some reports
have suggested that it might act as an endogenous
tumor promoter in vivo.11,12 In addition, data from 
the TNF- receptor type 1 knockout mouse model
have provided evidence of the essential role of TNF-
in carcinogenesis.13
Several SNPs in the TNF- promoter region,
including those located at −1031, −863, −857, −575,
−376, −308, −244, −238, +70, and +71 nucleotides
relative to the start site of transcription, have been
identified,14 and some of them are associated with
susceptibility to cancer.15–18 The expression of TNF-
can be regulated at the transcriptional level, and the
differences in TNF- production may be determined
at the genetic level. Differential transcriptional activity
and in vitro TNF- production were found in patients
carrying variants of SNPs at positions −1031, −863, 
−857, −308, and −238 in the TNF- promoter
region.19–22 Among these allelic variants, the −308
G/A allele has been extensively studied in terms of its
effects on TNF- gene regulation. The less common
−308A allele was found to be associated with high
baseline and induced expressions,19,20 and positive
associations were found between the −308A allele and
susceptibility to malignant tumors.15,16,18 Other vari-
ants of TNF- promoter SNPs are also related to high
TNF- production.22 To evaluate the associations
between these SNPs (with a focus on the variants of
the −308 allele) and susceptibility to NPC, we con-
ducted a case-control study in Taiwan.
Methods
Study population 
Between January 2000 and December 2004, we
recruited 89 consecutive patients with pathologically
confirmed primary NPC from the oncology ward at a
teaching hospital in Tainan, Taiwan. The extent of
involvement was evaluated by physical examination,
serologic markers of EBV, and imaging studies, includ-
ing conventional X-rays, sonography, whole-body bone
scan, computerized tomography scan, and magnetic
resonance imaging. Clinical staging was based on the
1997 American Joint Committee on Cancer staging
system.23 An indirect immunofluorescence assay was
used to test for IgA and IgG antibodies against the
EBV capsid antigen (anti-EBV IgA and anti-EBV IgG).
A titer less than 1:40 was considered to be negative
for anti-EBV IgA, and a titer less than 1:640 was con-
sidered to be negative for anti-EBV IgG. 
A total of 360 controls were recruited from par-
ticipants in a health check-up program. None of the
controls had a history of cancer or were found to have
cancer during the health check-up. The controls were
recruited during the study period consecutively, with-
out matching to the patients. All participants were
Taiwanese. Peripheral blood samples were taken from
patients and controls, and blood specimens, including
white blood cells and serum, were frozen at −70ºC
until analysis. Informed consent was obtained from
each participant included in this study, and the study
protocol conformed to ethical guidelines as reflected
by the approval of the institution’s research committee.
Determination of SNPs of the TNF-a
promoter region 
From the peripheral blood leukocytes of each partici-
pant, we extracted genomic DNA using a DNA isolation
kit (MBI Fermentas Ltd, Vinius, Lithuania), following
the manufacturer’s instructions. The −308 TNF- pro-
moter gene variants were determined by polymerase
chain reaction (PCR)-restriction fragment length poly-
morphism analysis. A 117-base pair fragment of the
TNF- promoter region spanning −238 to −308 sites
was generated by using 5-AGG CAA TAG GTT
TTG AGG GCC AT 3 and 5-ACA CTC CCC ATC
CTC CCT GCT C 3 as the primers. The thermocy-
cling conditions were as follows: 95ºC for 5 minutes;
95ºC for 15 seconds, 60ºC for 30 seconds, and 72ºC
for 30 seconds for 35 cycles, and then 72ºC for 
7 minutes. Restriction enzyme of Nco1 (Boehringer
Mannheim, Mannheim, Germany) digestion with the
PCR product was carried out overnight and then ana-
lyzed on a 3% agarose gel. DNA products were visual-
ized by ethidium bromide staining. An example of the
gel electrophoresis of different genotypes is shown in
Figure 1. The detailed method is described in our
previous report.18
Among the study participants, 23 NPC patients
and 50 controls were randomly chosen to determine
other SNPs of the TNF- promoter region. PCR was
performed using primers to amplify the sequences
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between −1065 and −101 nucleotides (NCBI acces-
sion no. M16441) relative to the TNF- transcrip-
tion start site, using the sense primer −1084: 5-GAT
GGA CTC ACC AGG TGA G 3 and the antisense
primer −81: 5-TCC TTG GTG GAG AAA CCC AT
3. The conditions of amplification were as follows:
95ºC for 5 minutes, 94ºC for 20 seconds, 57ºC for
20 seconds, and 72ºC for 60 seconds for 35 cycles,
followed by 72ºC for 10 minutes. PCR products
were purified using a Qiagen extraction kit. The frag-
ments were then directly sequenced using the ABI
Prism 377 DNA sequencer (PE Applied BioSystems,
Foster City, CA, USA).
Statistical analysis
The differences in the distributions of genotypes and 
−308A allele carriage among the different groups of
participants, defined by gender, age, and serologic
markers of EBV, were evaluated by the 2 test or
Fisher’s exact test. In addition, we calculated odds
ratios (ORs) for NPC associated with −308A allele
carriage for different groups defined by gender, age,
and serologic markers of EBV. The distributions of
the other variants of the TNF- promoter gene
between patients and controls were also evaluated by
the 2 test or Fisher’s exact test. All statistical analyses
were performed using an SAS package (SAS Institute,
Cary, NC, USA), with the 2-tailed significance level
set at 0.05. 
Results 
−308 TNF-a promoter gene polymorphism 
The 89 NPC patients had a median age of 50 years
(range, 30–79 years) at diagnosis, and 67 (75%) were
men. The 360 controls had a median age of 53 years
(range, 22–75 years), and 216 (60%) were men. In
comparison with the controls, the NPC patients were
younger and included a higher proportion of men.
On the basis of TNM staging, 6 (7%) patients were
stage I, 25 (28%) stage II, 31 (35%) stage III, and 
27 (30%) stage IV. Among patients and controls, the
−308G/G homozygote was the predominant geno-
type at position −308 of the TNF- promoter gene
(patients 78%, controls 80%), while the −308A/A
homozygote was uncommon (only 2 in the controls),
but the distribution of the −308 genotype was not
significantly different between the patients and con-
trols. In comparison with the controls, patients had 
a higher proportion of positive anti-EBV IgA tests
(86% vs. 6%, p < 0.001). Nonetheless, the positive rate
for anti-EBV IgG was similar between the NPC patients
and controls.
Among patients and controls, distributions of the
−308 genotypes and −308A allele carriage did not 
differ significantly in the subgroups defined by age,
gender, anti-EBV IgA, or anti-EBV IgG (Table 1).
The carriage of the −308A allele (in both homozygous
and heterozygous participants) was not associated with
an increased risk for NPC (OR, 1.2; 95% confidence
interval [CI], 0.7–2.0) in comparison with −308G
homozygosity (Table 2). Likewise, when patients and
controls were stratified according to gender, age, and
anti-EBV IgA, −308A allele carriage was not associ-
ated with increased ORs of developing NPC across all
strata (p > 0.05 for all tests) (Table 2).
Variants of SNPs in the TNF- promoter gene 
The sequence of the TNF- promoter region was
identified in 23 NPC patients and 50 controls. The
NPC patients had a median age of 51 years (range,
30–74 years) at diagnosis, and 19 (83%) were men.
The controls had a median age of 55 years (range,
32–75 years), and 37 (74%) were men. Among the 
73 TNF- promoter regions sequenced, we detected
a new SNP at position −806 with less common T
allele (Figure 2). We also observed variants of −1031, 
−863, and −857 SNPs of the TNF- promoter
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Figure 1. Polymerase chain reaction (PCR)–restriction fragment
length polymorphism analysis of the −308 TNF- promoter gene.
An Nco1 cleavage site in the −308G homozygote PCR product
resulted in 2 digested DNA bands of 95 and 22 bp (lane 1). The
heterozygote has 3 bands (117, 95, 22 bp) (lane 2). The homozy-
gote of −308A is not cleaved by Nco1 and has a single band with
a fragment of 117 bp (lane 3). Lane M = 100 bp ladder. 
region, but did not find −575, −376, −244, or −238
allelic variants. The −806T allele carrier rate was
much lower among NPC patients (OR, 0.3; 95% 
CI, 0.0–2.9), but the difference was not statisti-
cally significant. In fact, no significant differences in
these SNPs within the TNF- promoter region were
observed between the patients and controls in our
study (Table 3). 
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Table 1. Distributions of genotypes in patients with nasopharyngeal carcinoma (NPC) and controls according to gender, age, and sero-
logic markers for Epstein–Barr virus (EBV)
Characteristic
Controls NPC patients
−308G −308A allele 
p*
−308G −308A allele 
p*
homozygotes, n (%) carriers, n (%) homozygotes, n (%) carriers, n (%)
Gender 0.451 0.379
Men 170 (79) 46 (21) 50 (75) 17 (25)
Women 118 (82) 26 (18) 19 (86) 3 (14)
Age (yr) 0.229 0.643
< 50 119 (83) 24 (17) 36 (80) 9 (20)
50–64 112 (76) 36 (24) 22 (79) 6 (21)
> 64 57 (83) 12 (17) 11 (69) 5 (31)
Anti-EBV IgA† 0.508 0.286
Positive 3 (75) 1 (25) 60 (80) 15 (20)
Negative 50 (85) 9 (15) 8 (67) 4 (33)
Anti-EBV IgG† > 0.95 0.391
Positive 50 (83) 10 (17) 67 (79) 18 (21)
Negative 3 (100) 0 (0) 1 (50) 1 (50)
*Fisher’s exact test or x2 test; †serologic data of EBV were available for 87 patients and 63 controls. Anti-EBV IgA = IgA antibodies against EBV capsid antigen;
Anti-EBV IgG = IgG antibodies against EBV capsid antigen.
Table 2. Odds ratios for nasopharyngeal carcinoma (NPC) patients associated with −308A allele carriage by gender, age, and serologic 
markers for Epstein–Barr virus (EBV)
Group Controls, n (%) NPC patients, n (%) Odds ratio [95% CI] p*
All participants 72 (20) 20 (23) 1.2 [0.7, 2.0]
Gender 0.442
Men 46 (21) 17 (25) 1.3 [0.7, 2.4]
Women 26 (18) 3 (14) 0.7 [0.2, 12.6]
Age (yr) 0.501
< 50 24 (17) 9 (20) 1.2 [0.5, 2.9]
50–64 36 (24) 6 (21) 0.8 [0.3, 2.3]
> 64 12 (17) 5 (31) 2.2 [0.6, 7.4]
Anti-EBV IgA† 0.333
Positive 1 (25) 15 (20) 2.8 [0.7, 11.2]
Negative 9 (15) 4 (33) 0.8 [0.1, 7.7]
Anti-EBV IgG† 0.230
Positive 10 (17) 18 (21) 1.3 [0.6, 3.2]
Negative 0 (0) 1 (50) —
*Breslow-Day test for the homogeneity of the odds ratio; †serologic data of EBV were available for 87 patients and 63 controls. CI = confidence interval; Anti-
EBV IgA = IgA antibodies against EBV capsid antigen; Anti-EBV IgG = IgG antibodies against EBV capsid antigen.
Figure 2. Direct sequencing data identify a novel SNP at the posi-
tion of  −806 in the TNF- promoter gene. 
Discussion 
Taiwan is a hyperendemic area for NPC. While some
cases may be attributable to environmental factors, such
as smoking, EBV infection, and Cantonese salted foods,
host susceptibility may also play an important role. A
study in Taiwan showed that first-degree relatives of
NPC patients had a relative risk of 19.2 for developing
NPC.2 More and more genetic polymorphisms have
been found to be associated with NPC, including
cytochrome P450 2E1, glutathione S-transferase M1,
and DNA repair enzymes XRCC1 and hOGG1.3–5
NPC has been found to be associated with HLA
genes, particularly HLA-A*0207 and -B*4601 alleles,7
and therefore it is suggested that other candidate genes
might lie within or near HLA. Since nearly all NPC
tumors are EBV-positive, it is postulated that individu-
als who inherit HLA alleles with a different ability to
present EBV antigens to the immune system might be
at different risk for developing NPC. The TNF- gene
is located in the major histocompatibility complex III
gene region of chromosome 6, between the HLA-B
and HLA-DR genes.6,7 TNF- is a pro-inflammatory
cytokine, and evidence implicates the role of TNF- in
inflammatory pathways that increase tumorigenesis.8
The production of TNF- could be influenced by
TNF- promoter gene polymorphisms, and therefore
TNF- promoter polymorphisms may play a role in the
pathogenesis of NPC. In the current study, we found
that the frequency of the −308A allele of the TNF-
promoter gene is similar in the NPC patients compared
to the controls, which indicates that the −308A allele
of the TNF- promoter gene is not a candidate bio-
marker for susceptibility to NPC. This observation is in
agreement with 2 previous studies,24,25 and when we
combined these 2 studies with the current study, we
did not observe a significant difference in −308G/A
distribution between a total of 277 NPC patients and
770 controls. In the previous 2 reports, however, no
analyses of the distributions of −308 genotypes and
allele carriage among different groups of participants,
defined by gender, age, and serologic markers of EBV,
were done. Studies on some other types of cancer,
including breast carcinoma, hepatocellular carcinoma,
and prostate carcinoma, have found associations with 
−308A allele carriage.15,16,18 However, no association
was observed in gastric cancer, uterine cervical cancer,
and some hematologic malignancies.17,26 These find-
ings may reflect the differing carcinogeneses of differ-
ent types of cancer or of different populations.
Recently, at least 10 SNPs in the TNF- promoter
gene have been identified, and some of these SNPs
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Table 3. Genotype frequencies of SNPs in the promoter region of TNF- in nasopharyngeal carcinoma (NPC) patients and controls 
Genotype NPC patients, n (%) Controls, n (%) Odds ratio [95% CI] p*
−1031 0.894
T/T 16 (70) 34 (68) 1
T/C 7 (30) 16 (32) 0.9 [0.3, 2.7]
C/C 0 (0) 0 (0) NA
−863 0.683
C/C 15 (65) 35 (70) 1
C/A 8 (35) 15 (30) 1.2 [0.4, 3.6]
A/A 0 (0) 0 (0) NA
−857 0.865
C/C 17 (74) 36 (72) 1
C/T 6 (26) 14 (28) 0.9 [0.3, 2.8]
T/T 0 (0) 0 (0) NA
−806 0.421
C/C 22 (96) 44 (88) 1
C/T 1 (4) 6 (12) 0.3 [0.0, 2.9]
T/T 0 (0) 0 (0) NA
−308 0.695
G/G 18 (78) 37 (74) 1
G/A 5 (22) 13 (26) 0.8 [0.2, 2.6]
A/A 0 (0) 0 (0) NA
*x2 test or Fisher’s exact test. CI = confidence interval; NA = not available.
may affect TNF- promoter activity relative to high
TNF- production,21,22 although the actual biologic
effect of these polymorphisms in vivo has not been
clearly demonstrated. In the current study, we found 
a new SNP located at the −806 locus relative to the 
TNF- transcription site. The −806 locus was reported
by another research team at our institution with an
allele frequency of 1% among 524 dyspeptic patients.27
We conducted a search of the literature for this allele
on MEDLINE but failed to locate any other article.
The frequency of this allele was 12% among the normal
controls in our study and was significantly higher 
than the 1% cut-off for defining SNP (p < 0.01), indi-
cating that it is very likely to be a novel SNP. We found
that the carriage of the −806T allele was associated
with a decreased OR of 0.3 in developing NPC, but the
result did not achieve statistical significance. The sam-
ple size of our study might limit the statistical power to
determine whether the carriage plays a protective role
in the development of NPC. Further assessments of 
−806T allele frequencies in other ethnic populations
and the biologic functions of this SNP are warranted.
TNF- promoter SNPs were reported to be associ-
ated with the susceptibility to, or the severity of some
diseases such as psoriasis, adult periodontitis, human
immunodeficiency virus type 1 viremia, and juvenile
rheumatoid arthritis.21,28–30 Some variants have even
been found to be associated with susceptibility to 
certain malignant tumors.17,31,32 Nonetheless, we
observed no association between any of these SNPs 
and NPC. Whereas our previous study found that 
the allele frequency of −308A was lower in Chinese
than in Caucasians;18 differences in the allele frequen-
cies of −1031C, −863A, and −857T between the 
2 groups need to be investigated further. Baena et al14
documented the ethnic-specific patterns of TNF-
promoter SNPs, which can be used as markers of
human ancestry.14 We conducted a search of PubMed
using combinations of the key words “TNF-” and
“polymorphism” and identified 4 reports with data
on these allele frequencies among healthy Chinese
populations33–36 (Table 4). The weighted average of
carriage rates was 36% for allelic variants of −1031C,
32% for −863A, and 29% for −857T. No significant
differences were found among these SNPs in our
NPC patients and pooled reference Chinese controls,
which indicated that our controls were representative
of the general Chinese population in terms of the
allele frequencies. Therefore, the selection of controls
in our study did not affect the outcomes. 
In conclusion, our study found no association
between the TNF- promoter SNPs and NPC. This
indicates that these variants of the TNF- promoter
may not be used as biomarkers to identify individuals
who are more susceptible to NPC. However, the role
of the novel −806T allele in the regulation of TNF-
production and its association with diseases need to
be investigated further.
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